Literature DB >> 21847627

Associations between cytotoxic T lymphocyte-associated antigen-4 polymorphisms and serum tumor necrosis factor-α and interferon-γ levels in patients with chronic hepatitis B virus infection.

Qunying Han1, Shaoqiong Duan, Guoyu Zhang, Zhu Li, Na Li, Qianqian Zhu, Yi Lv, Jinghong Chen, Zhengwen Liu.   

Abstract

BACKGROUND: Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) polymorphism, which may affect host immune response including cytokines production, is thought to be associated with hepatitis B virus (HBV) infection. This study investigated the associations between CTLA4 polymorphism and serum tumor necrosis factor (TNF)-α and interferon (IFN)-γ levels in patients with chronic HBV infection.
METHODS: CTLA4 promoter -318C/T and exon 1 +49A/G polymorphisms and serum TNF-α and IFN-γ levels were determined in 172 patients with chronic HBV infection and 145 healthy controls.
RESULTS: The genotype of CTLA4 -318C/T polymorphism had no association to TNF-α and IFN-γ levels. Serum levels of TNF-α and IFN-γ in chronic HBV patients with +49GG genotype were lower than those with +49AG genotype (p = 0.030 and p = 0.042, respectively), and haplotypes -318C + 49A and -318C + 49G seemed to have no significant effects on TNF-α and IFN-γ levels.
CONCLUSIONS: CTLA4 +49GG genotype was associated to lower TNF-α and IFN-γ levels in patients with chronic HBV infection but this association was diminished by haplotype formation with -318C/T alleles, indicating that the influence of CTLA4 -318C/T and +49A/G polymorphisms on the susceptibility and disease progress of chronic HBV infection may not be effectuated by affecting TNF-α and IFN-γ secretion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21847627     DOI: 10.1007/s00011-011-0368-8

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  44 in total

1.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.

Authors:  Hironori Ueda; Joanna M M Howson; Laura Esposito; Joanne Heward; Hywel Snook; Giselle Chamberlain; Daniel B Rainbow; Kara M D Hunter; Annabel N Smith; Gianfranco Di Genova; Mathias H Herr; Ingrid Dahlman; Felicity Payne; Deborah Smyth; Christopher Lowe; Rebecca C J Twells; Sarah Howlett; Barry Healy; Sarah Nutland; Helen E Rance; Vin Everett; Luc J Smink; Alex C Lam; Heather J Cordell; Neil M Walker; Cristina Bordin; John Hulme; Costantino Motzo; Francesco Cucca; J Fred Hess; Michael L Metzker; Jane Rogers; Simon Gregory; Amit Allahabadia; Ratnasingam Nithiyananthan; Eva Tuomilehto-Wolf; Jaakko Tuomilehto; Polly Bingley; Kathleen M Gillespie; Dag E Undlien; Kjersti S Rønningen; Cristian Guja; Constantin Ionescu-Tîrgovişte; David A Savage; A Peter Maxwell; Dennis J Carson; Chris C Patterson; Jayne A Franklyn; David G Clayton; Laurence B Peterson; Linda S Wicker; John A Todd; Stephen C L Gough
Journal:  Nature       Date:  2003-04-30       Impact factor: 49.962

Review 2.  Hepatitis B virus infection--natural history and clinical consequences.

Authors:  Don Ganem; Alfred M Prince
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

3.  Haplotype analysis can provide improved clinical information than single genotype analysis.

Authors:  Valeria Cristina Sandrim; Jose Eduardo Tanus-Santos
Journal:  Thromb Res       Date:  2006-12-14       Impact factor: 3.944

4.  High IFN-gamma production of individual CD8 T lymphocytes is controlled by CD152 (CTLA-4).

Authors:  Pushpa Pandiyan; J Kolja E Hegel; Manuela Krueger; Dagmar Quandt; Monika C Brunner-Weinzierl
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

5.  Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells.

Authors:  C A Piccirillo; E M Shevach
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

Review 6.  Immune responses in hepatitis B virus infection.

Authors:  Barbara Rehermann
Journal:  Semin Liver Dis       Date:  2003-02       Impact factor: 6.115

7.  Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection.

Authors:  Chloe L Thio; Timothy L Mosbruger; Richard A Kaslow; Christopher L Karp; Steffanie A Strathdee; David Vlahov; Stephen J O'Brien; Jacquie Astemborski; David L Thomas
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

8.  CD152 (CTLA-4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin.

Authors:  Johannes K Hegel; Karin Knieke; Paula Kolar; Steven L Reiner; Monika C Brunner-Weinzierl
Journal:  Eur J Immunol       Date:  2009-03       Impact factor: 5.532

9.  Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response.

Authors:  Jeroen N Stoop; Andrea M Woltman; Paula J Biesta; Johannes G Kusters; Ernst J Kuipers; Harry L A Janssen; Renate G van der Molen
Journal:  Hepatology       Date:  2007-09       Impact factor: 17.425

10.  Selective expansion of cytotoxic T lymphocytes with a CD4+CD56+ surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with Hepatitis B virus.

Authors:  V Barnaba; A Franco; M Paroli; R Benvenuto; G De Petrillo; V L Burgio; I Santilio; C Balsano; M S Bonavita; G Cappelli
Journal:  J Immunol       Date:  1994-03-15       Impact factor: 5.422

View more
  3 in total

1.  Effect of cytotoxic T-lymphocyte antigen-4, TNF-alpha polymorphisms on osteosarcoma: evidences from a meta-analysis.

Authors:  Jianwei Liu; Junli Wang; Weiping Jiang; Yujin Tang
Journal:  Chin J Cancer Res       Date:  2013-12       Impact factor: 5.087

Review 2.  Relationship between cytokine gene polymorphisms and chronic hepatitis B virus infection.

Authors:  Semra Tunçbilek
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

3.  Distribution of Cytotoxic T Lymphocyte-Associated Antigen-4 Promoter Polymorphisms in Taiwanese Patients with Type 2 Diabetes Mellitus.

Authors:  Yung-Luen Shih; Hsu-Feng Lu; Chiao-Wan Hsiao; Kuo-Ting Ho; Pei-Chi Chen; Chien-Ning Huang; Yuanmay Chang; Shang-Jyh Kao; Ming-Yuh Shiau; Yih-Hsin Chang
Journal:  Int J Med Sci       Date:  2018-02-12       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.